Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Fact checked by Russ Conroy
News
Article

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

A next-generation pancreatic cancer blood test elicited positive results, detecting significantly more cancers than CA19-9 in patients with pancreatic cancer in the VERIFI study, according to a press release from Immunovia.1

The test detected 77% of stage I and II pancreatic cancer, which exceeded the study’s target goal of 65% (P = .005); it also improved over the sensitivity of CA19-9, a common biomarker for pancreatic cancer, which had a detection rate of 69% (P = .0126).2 The specificity rates were 88% with the blood test and 89% with CA19-9.

The specificity of the test was 88%, which did not exceed the pre-defined success criteria of 90%. Reasons cited for this included a much smaller cohort of control patients; CA19-9 levels in VERIFI controls being different than the CLARITI study’s controls; and VERIFI including a higher percentage of patients with pancreatic cysts, who are harder to diagnose.

Across various high-risk patient subgroups, the blood test showed “excellent and consistent” sensitivity and specificity: overall (n = 317), the sensitivity was 78%, and the specificity was 92%; in the group with familial history or genetic risk (n = 71), the sensitivity was 78%, and the specificity was 94%; in the group with diabetes (n = 128), the sensitivity was 80%, and the specificity was 90%; and in the group with cysts (n = 79), the sensitivity was 72%, and the specificity was 89%.

Data came from the VERIFI and CLARITI validation studies, and full results were shared in a company webcast.2

“The Immunovia test accurately classified cancerous and non-cancerous blood samples in the VERIFI study,” Jeff Borcherding, chief executive officer at Immunovia, stated in the press release.1 “The test once again significantly outperformed CA19-9. In addition, combined results from the CLARITI and VERIFI studies make it clear that our next-generation test can accurately detect pancreatic cancer in multiple different groups of high-risk individuals.”

The VERIFI study compared a total of 385 rare blood samples, 115 of whom had stage I and II pancreatic ductal adenocarcinoma (PDAC) and 270 of whom made up the high-risk, non-cancerous control group.

The primary end point of the VERIFI study was sensitivity, defined as the ability to detect stage I and II PDAC in the case samples. Secondary end points included specificity, defined as whether the test correctly classified the control samples as non-cancerous, and performance vs CA19-9, defined as whether the blood test provided higher sensitivity than CA19-9 at equal specificity.

The CLARITI study was the first successful clinical trial to evaluate Immunovia’s pancreatic cancer blood test.

CA19-9 elicited a sensitivity of 66% in the overall group (P <.001), 66% in the familial/genetic group (P = .0114), 72% in the diabetes group (P = .0075), and 62% in the cysts group (P = .0047). The CA19-9 specificity rates were 93%, 94%, 89%, and 93% (P = .0093), respectively. The Immunovia blood test was superior in all values except for overall specificity and cysts, where it was inferior, and familial/genetic specificity, where it was equal.

Regarding detection of stage I and II pancreatic cancer, historical control data have shown that endoscopic ultrasound had a sensitivity of 100% and a specificity of 82%, MRI had a sensitivity of 50% and a specificity of 91%, and CT had a sensitivity of 50% and a specificity of 86%.3,4

These results will be used to support regulatory submissions and payer reimbursement efforts.

References

  1. Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test. News release. Immunovia. March 24, 2025. Accessed March 25, 2025. https://tinyurl.com/njjnwff4
  2. VERIFI validation study results review. Immunovia. March 24, 2025. Accessed March 25, 2025. https://tinyurl.com/ywterafp
  3. Sakamoto H, Kitano M, Suetomi Y, Maekawa K, Takeyama Y, Kudo M. Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas. Ultrasound Med Biol. 2008;34(4):525-532. doi:10.1016/j.ultrasmedbio.2007.09.018
  4. Borbath I, Van Beers BE, Lonneux M, et al. Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. Pancreatol. 2005;5(6):533-561. doi:10.1159/000087497
Recent Videos
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Related Content